{"entity":{"id":"nct06267729","kind":"trial","name":"Study of AZD0754 in Participants With Metastatic Prostate Cancer","aka":[],"tldr":"A phase 1/2 trial of AZD0754 in prostate cancer, run by AstraZeneca, now recruiting.","summary":"Study of AZD0754 in Participants With Metastatic Prostate Cancer is a phase 1/2 interventional study registered as NCT06267729 by AstraZeneca, with 60 participants planned, started 2024-03-12 and due to reach its primary completion in 2026-11-24. Interventions recorded: AZD0754 and AZD2287.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06267729","url":"https://clinicaltrials.gov/study/NCT06267729"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06267729","phase":"1/2","setting":"A Phase I/II Open Label Study to Evaluate the Safety, Cellular Kinetics, and Efficacy of AZD0754, a Chimeric Antigen Receptor (CAR) T-cell Therapy Directed Against STEAP2, in Adult Participants With Metastatic Prostate Cancer: APOLLO","sponsor":"AstraZeneca","enrolled":60,"outcomes":[]},"route":"/trials/nct06267729/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}